Delcath Systems 株価情報 (NASDAQ: DCTH)

最新ニュース Delcath Systems (NASDAQ:DCTH) 株価情報

Delcath Systems

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems Inc

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
Shares of MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell sharply in today's pre-market trading following the company's announcement to issue more shares to finance additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions. This move aligns with MicroStrategy's ongoing strategy to <a href="https://www.benzinga.com/quote/MSTR">bolster its Bitcoin reserves</a>.
MicroStrategy shares fell 3.5% to $345.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares dipped 10.1% to $10.01 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) declined 10% to $10.21 in pre-market trading.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 8.6% to $5.80 in pre-market trading.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) fell 8.6% to $11.21 in pre-market trading.</li>
<li>SunCoke Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXC#NYSE">SXC</a>) dipped 8.2% to $9.90 in pre-market trading.</li>
<li>Gray Television, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) fell 5.9% to $2.8505 in pre-market trading.</li>
<li>Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) slipped 2.5% to $42.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

CGEM

DCTH

DSGN

MSTR

NPCE

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) rose sharply in today's pre-market trading after it reported a 43% year-on-year growth in bookings for November 2024, primarily driven by increased wedding <a href="https://www.benzinga.com/quote/ZCAR/news">season demand</a>.
Zoomcar shares jumped 142% to $3.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) gained 161% to $0.5775 in pre-market trading. SciSparc said AutoMax received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Millennium Group International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIH#NASDAQ">MGIH</a>) gained 153% to $3.8800 in pre-market trading after gaining 10% on Tuesday.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 94% to $4.20 in pre-market trading after the company announced a prominent member of the UAE&#8217;s royal family, has joined the company as an independent director.</li>
<li>SMX (Security Matters) Public Limited Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NYSE">SMX</a>) shares jumped 69.3% to $0.3690 in pre-market trading.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 48% to $2.04 in pre-market trading after jumping around 10% on Tuesday.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) rose 35.7% to $0.2851 in pre-market trading after gaining around 24% on Tuesday.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 36.3% to $0.9689 in pre-market trading after surging around 36% on Tuesday.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 25.8% to $12.32 in pre-market trading after gaining more than 5% on Tuesday.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) rose 17.8% to $1.12 in pre-market trading after falling around 8% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hour Loop, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) shares tumbled 30.5% to $3.0600 in pre-market trading after jumping 203% on Tuesday.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) fell 28.8% to $6.52 in pre-market trading. Carbon Revolution shares jumped 135% on Tuesday after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) declined 25.7% to $1.12 in pre-market trading after jumping around 63% on Tuesday.</li>
<li>Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) fell 25.7% to $5.26 in today's pre-market trading after jumping 310% on Tuesday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares dipped 25.1% to $1.64 in pre-market trading. Meiwu Technology regained compliance with Nasdaq Listing Rule, which requires ordinary shares to maintain minimum bid price.</li>
<li>Luokung Technology Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKCO#NASDAQ">LKCO</a>) dipped 21.1% to $1.3500 in pre-market trading after gaining over 4% on Tuesday.</li>
<li>TCTM Kids IT Education Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares fell 21.1% to $0.5979 in pre-market trading.</li>
<li>Brera Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BREA#NASDAQ">BREA</a>) fell 18.1% to $0.8190 in pre-market trading after gaining over 42% on Tuesday.</li>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares fell 10.1% to $10.01 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) fell 10% to $10.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

AIRE

BAOS

BREA

CREV

HOUR

LICN

LKCO

MGIH

SOBR

SPRC

SVRE

TCTM

ZCAR

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO&#x2122; in combination with standard of care (SOC) for liver-dominant metastatic colorectal cancer (mCRC). With the FDA's review complete, Delcath is now authorized to initiate patient enrollment.
The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. Approximately 90 patients will be enrolled in this randomized, controlled trial. The study will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the second half of 2025. The trial's primary endpoint, hepatic progression-free survival (hPFS), is anticipated to read out by the end of 2027, while overall survival (OS), a secondary endpoint, is expected in 2028.
The company estimates that the total addressable market (TAM) for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States. This market includes patients who present with significant liver disease burden, with liver-dominant status determined through radiological and clinical criteria. By targeting this patient population, Delcath aims to provide a novel treatment option for those with limited therapeutic alternatives.

Biotech

General

Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 94.74 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $11.20 million which beat the analyst consensus estimate of $10.46 million by 7.08 percent. This is a 2.48K percent increase over sales of $434.00 thousand the same period last year.

Earnings

Delcath Systems Q3 2024 GAAP EPS $(0.06) Beats $(0.23) Estimate, Sales $11.20M Beat $10.46M Estimate

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Delcath Systems will report an earnings per share (EPS) of $-0.22. 
The market awaits Delcath Systems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.12, leading to a 4.93% drop in the share price on the subsequent day.
Here's a look at Delcath Systems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.47</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.48</td>
<td>-1.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>10.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006227_0.png" alt="eps graph" />
<h3>Market Performance of Delcath Systems's Stock</h3>
Shares of Delcath Systems were trading at $10.94 as of November 06. Over the last 52-week period, shares are up 274.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Delcath Systems</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Delcath Systems.
The consensus rating for Delcath Systems is Buy, derived from 2 analyst ratings. An average one-year price target of $21.5 implies a potential 96.53% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Pulmonx, AngioDynamics and Zynex, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Pulmonx, with an average 1-year price target of $16.0, indicating a potential 46.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for AngioDynamics, with an average 1-year price target of $13.33, suggesting a potential 21.85% upside.</li>
<li>Zynex is maintaining an Buy status according to analysts, with an average 1-year price target of $14.67, indicating a potential 34.1% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Pulmonx, AngioDynamics and Zynex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>1468.89%</td>
<td>$6.25M</td>
<td>-146.09%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>15.39%</td>
<td>$15.03M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>0.10%</td>
<td>$39.79M</td>
<td>6.95%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Delcath Systems ranks first in revenue growth among its peers. It has the lowest gross profit margin. Delcath Systems has the lowest return on equity.
<h3>Delving into Delcath Systems's Background</h3>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Breaking Down Delcath Systems's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Delcath Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -146.09%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -39.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Delcath Systems's debt-to-equity ratio is below the industry average. With a ratio of 1.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/DCTH/earnings">To track all earnings releases for Delcath Systems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Delcath Systems's Earnings Preview

4 analysts have shared their evaluations of Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $25.00 and a low estimate of $21.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1729263675_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Delcath Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Delcath Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Delcath Systems's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Delcath Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Delcath Systems</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Delcath Systems's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -146.09%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Delcath Systems's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -39.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.33.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Delcath Systems

Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $21 price target.

Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target

WIIM

Delcath Systems shares are trading higher after the company announced better-than-expected preliminary Q3 revenue results.

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) sees Q3 sales of $11.200 million vs $9.45 million estimate.

Guidance

Delcath Systems Sees Q3 2024 Preliminary Sales $11.200M vs $9.45M Est

Delcath Systems Highlights Presentation Of Data At ESMO 2024 Demonstrating Efficacy Of HEPZATO KIT For Metastatic Uveal Melanoma Subgroups

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said, &#8220;This is a very speculative situation,&#8221; when asked about ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>). &#8220;Any time there's immunity-compromised patients, there's some <a href="https://www.benzinga.com/quote/ADMA">big money down the road,&#8221; he added.</a>
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates. 
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
&#8220;This is one of those situations that is very difficult,&#8221; Cramer on MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>). &#8220;If they don't pull out of the tailspin of losses, then it just doesn't matter.&#8221;
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), he said, &#8220;There's no investing. At this point, it is speculating.&#8221;
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
<ul>
<li>ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.</li>
<li>MP Materials shares gained 3.2% to close at $12.90.</li>
<li>Delcath Systems shares gained 1.2% to close at $10.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ADMA

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics

Delcath Systems Announces Results from Independent Study On Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems shares are trading higher after the company published a study by investigators in the Annals Of Surgical Oncology.

Key Findings from the Study:
<ul>
<li>Overall Survival (OS): The study reported median OS of 22.4 months for patients treated with HEPZATO KIT as a first-line therapy (N=17) and 18.4 months as a second-line therapy (N=6).</li>
<li>Hepatic Progression-Free Survival (hPFS): Patients receiving HEPZATO KIT as first-line therapy had a median hPFS of 17.6 months (N=17), compared to 8.8 months (N=6) for immunotherapy and 9.2 months (N=7) for other liver-directed therapies. When used as a second-line therapy, HEPZATO KIT resulted in a median hPFS that was not reached (N=6), showing better outcomes than immunotherapy (14.7 months, N=5) and other liver-directed therapies (7.5 months, N=3) in this patient cohort.</li>
<li>Progression-Free Survival (PFS): The median overall PFS was 15.4 months (N=17) for patients receiving HEPZATO KIT as first-line therapy, compared to 8.8 months (N=6) for immunotherapy and 9.2 months (N=7) for other liver-directed therapies. In the second-line setting, HEPZATO KIT resulted in a median PFS of 22.2 months (N=6), compared to 14.7 months (N=5) for immunotherapy and 7.5 months (N=3) for other liver-directed therapies, reflecting longer disease control in this group.</li>
</ul>

Delcath Systems Publishes Retrospective Study By Independent Investigators In The Annals Of Surgical Oncology. The Study, Titled "Hepatic And Overall Progression-free Survival After Percutaneous Hepatic Perfusion (PHP) As First-line Or Second-line Therapy For Metastatic Uveal Melanoma,"

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) ("Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal of Gastrointestinal Oncology. The study, titled "Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation," highlights the efficacy and safety of repeated chemosaturation treatments using Delcath's CHEMOSAT&#xAE; Hepatic Delivery System.
Key Findings from the Independent Study:
<ul>
<li>Patient Population: This retrospective study evaluated the efficacy of CHEMOSAT in 33 previously treated patients with unresectable intrahepatic metastases from various cancers: uveal melanoma (N=19), cholangiocarcinoma (N=8), hepatocellular carcinoma (N=2), and one patient each with ciliary body melanoma, acinar cell carcinoma, pancreatic cancer, or tonsil cancer (N=4). In addition to hepatic metastases, 7 out of 33 patients also had limited extrahepatic disease, which was found not to significantly impact overall survival.</li>
<li>Disease Control Rate: The study reported a disease control rate (DCR) of 91%, with 30 out of 33 patients experiencing either objective tumor response or stable disease. Notably, 6 patients (18.2%) achieved complete response (CR) in the liver, including 5 patients with uveal melanoma and 1 patient with cholangiocarcinoma, who received a median of 5 treatment cycles.</li>
<li>Hepatic Progression-Free Survival: Median hepatic progression-free survival (hPFS) was 52 weeks across all patients, with particularly strong outcomes for specific cancers:
<ul>
<li>69 weeks (16 months) median hPFS in patients with uveal melanoma.</li>
<li>38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma.</li>
</ul>
</li>
<li>Importance of Repeated Treatments: The investigators' approach of using CHEMOSAT in the form of regularly repeated treatment cycles as clinically indicated (Figure 1), similar to systemic chemotherapy, resulted in long-term disease control in the majority of patients and was well tolerated.</li>
<li>Tolerability and Safety: The safety profile of CHEMOSAT was consistent with published literature. Most patients experienced transient hematological adverse events, which were routinely managed with supportive care. Importantly, no significant liver damage was reported, even in patients who underwent multiple treatment cycles. Treatment was discontinued in 2 patients due to adverse events, and 2 patients withdrew consent during the treatment period.</li>
</ul>

Delcath Systems Announces Publication Of An Independent Study Conducted By Investigators At The University Hospital Of Leipzig, Germany, Titled "Hepatic Chemosaturation With Melphalan In Patients With Primary Or Secondary Liver Tumors With Or Without Extrahepatic Tumor Manifestation,"

Stephens &amp; Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Overweight and maintains $25 price target.

Stephens & Co. Reiterates Overweight on Delcath Systems, Maintains $25 Price Target

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.75, a high estimate of $25.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 3.57% from the previous average price target of $21.00.
<img src="https://www.benzinga.com/files/images/story/2024/1722945615_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Delcath Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$25.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Delcath Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Delcath Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Delcath Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Delcath Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DCTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delcath Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Delcath Systems: A Closer Look</h2>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Delcath Systems: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Delcath Systems displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 425.8%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Delcath Systems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -353.97%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -73.11%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -29.74%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Delcath Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Delcath Systems: Insights From 4 Financial Analysts

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Delcath Systems, Inc. ( ($DCTH) ) has released its Q3 earnings. Here is a breakdown of the information Delcath Systems, Inc. presented to its inves...

Delcath Systems Reports Strong Q3 Growth and Expansion

Delcath Systems (DCTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 8. Analyst John Newman ...

Delcath Systems' Strong Financial Performance and Expansion Plans Justify Buy Rating and $21 Price Target

Craig-Hallum analyst Chase Knickerbocker assigned a Buy rating to the stock today. The company's shares closed yesterday at $9.96. According to Tip...

Delcath Systems (DCTH) Gets a Buy from Craig-Hallum

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath Systems (DCTH) announced that the U.S. Food and Drug Administration FDA has completed its 30-day review of the Company's Investigational Ne...

FDA finishes review of Delcath's IND application of HEPZATO combo trial

Canaccord Genuity analyst John Newman maintained a Buy rating on Delcath Systems (DCTH – Research Report) yesterday and set a price target of $21.0...

Delcath Systems Receives Buy Rating: HEPZATO's Promising Phase 2 Trial and $2 Billion Market Opportunity

In a report released on December 3, Chase Knickerbocker from Craig-Hallum assigned a Buy rating to Delcath Systems (DCTH – Research Report). The co...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND – Research Report), BioLife ...

Comments

Delcath Systems

ニュース

最新ニュース Delcath Systems (NASDAQ:DCTH) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル